[go: up one dir, main page]

NO20071619L - Fremgangsmate for fremstilling av indazol forbindelse - Google Patents

Fremgangsmate for fremstilling av indazol forbindelse

Info

Publication number
NO20071619L
NO20071619L NO20071619A NO20071619A NO20071619L NO 20071619 L NO20071619 L NO 20071619L NO 20071619 A NO20071619 A NO 20071619A NO 20071619 A NO20071619 A NO 20071619A NO 20071619 L NO20071619 L NO 20071619L
Authority
NO
Norway
Prior art keywords
preparation
indazole compound
formula
indazole
compounds
Prior art date
Application number
NO20071619A
Other languages
English (en)
Inventor
Nebojsa Slobodan Stankovic
Mark Bryan Mitchell
Brigitte Leigh Ewanicki
Erik Jon Flahive
Annie Judith Kasparian
Stacy Ann O'neill-Slawecki
Neal William Sach
James Edward Saenz
Bing Shi
Jayaram Kasturi Srirangam
Qingping Tian
Shu Yu
Michael David Perry
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20071619L publication Critical patent/NO20071619L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Det beskrives framgangsmåter for framstilling av indazol-forbindelser av formel I-a, som er nyttige som modulatorer og/eller inhibitorer av proteinkinaser. Oppfinnelsen vedrører også mellomprodukter i fremstillingen av forbindelsene av formel I-a.
NO20071619A 2004-11-02 2007-03-28 Fremgangsmate for fremstilling av indazol forbindelse NO20071619L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62463504P 2004-11-02 2004-11-02
US71707105P 2005-09-14 2005-09-14
PCT/IB2005/003297 WO2006048744A1 (en) 2004-11-02 2005-10-21 Methods of preparing indazole compounds

Publications (1)

Publication Number Publication Date
NO20071619L true NO20071619L (no) 2007-04-25

Family

ID=35744929

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071619A NO20071619L (no) 2004-11-02 2007-03-28 Fremgangsmate for fremstilling av indazol forbindelse

Country Status (14)

Country Link
US (1) US7232910B2 (no)
EP (1) EP1809621A1 (no)
JP (1) JP2008518900A (no)
KR (1) KR20070058690A (no)
AR (1) AR051754A1 (no)
AU (1) AU2005300310A1 (no)
BR (1) BRPI0518203A2 (no)
CA (1) CA2586174A1 (no)
IL (1) IL182693A0 (no)
MX (1) MX2007005291A (no)
NO (1) NO20071619L (no)
RU (1) RU2007116107A (no)
TW (1) TWI294421B (no)
WO (1) WO2006048744A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2134702B2 (en) 2007-04-05 2023-08-30 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
CA2701292C (en) * 2007-10-25 2015-03-24 Genentech, Inc. Process for making thienopyrimidine compounds
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
KR101829595B1 (ko) 2009-01-08 2018-02-14 메르크 파텐트 게엠베하 3-（1-｛3-［5-（1-메틸-피페리딘-4일메톡시）-피리미딘-2-일］-벤질｝-6-옥소-1,6-디히드로-피리다진-3-일）-벤조니트릴 히드로클로라이드 염의 신규한 다형체 및 이의 제조 방법
KR20140069297A (ko) 2011-09-30 2014-06-09 화이자 인코포레이티드 N-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일-설파닐]-벤즈아미드의 약학 조성물
JP2014533262A (ja) 2011-11-11 2014-12-11 ファイザー・インク 慢性骨髄性白血病を治療するためのｎ−メチル−２−［３−（（ｅ）−２−ピリジン−２−イル−ビニル）−１ｈ−インダゾール−６−イルスルファニル］−ベンズアミド
US9899120B2 (en) 2012-11-02 2018-02-20 Nanotek Instruments, Inc. Graphene oxide-coated graphitic foil and processes for producing same
US10087073B2 (en) 2013-02-14 2018-10-02 Nanotek Instruments, Inc. Nano graphene platelet-reinforced composite heat sinks and process for producing same
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
CA2932757C (en) * 2013-12-06 2023-10-31 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
AU2015214390B2 (en) 2014-02-04 2020-05-07 Merck Sharp & Dohme LLC. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
ES2647262T3 (es) * 2014-03-31 2017-12-20 Senju Pharmaceutical Co. Ltd Derivado de alquinil indazol y uso del mismo
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2016108106A1 (en) * 2014-12-29 2016-07-07 Shilpa Medicare Limited An improved process for preparation of axitinib
CN112263677A (zh) 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent GmbH Pd-l1 antagonist combination treatments
EP3522923A1 (en) 2016-10-06 2019-08-14 Pfizer Inc Dosing regimen of avelumab for the treatment of cancer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
EA202192731A1 (ru) 2019-04-18 2022-02-04 Синтон Б.В. СПОСОБ ПОЛУЧЕНИЯ АКСИТИНИБА, СПОСОБ ОЧИСТКИ ПРОМЕЖУТОЧНОГО СОЕДИНЕНИЯ 2-((3-ЙОД-1H-ИНДАЗОЛ-6-ИЛ)ТИО)-N-МЕТИЛБЕНЗАМИДА, СПОСОБ ОЧИСТКИ АКСИТИНИБА ЧЕРЕЗ HCl СОЛЬ АКСИТИНИБА, ТВЕРДАЯ ФОРМА HCl СОЛИ АКСИТИНИБА
CA3254037A1 (en) 2022-03-03 2023-09-07 Pfizer MULTISPECIFIC ANTIBODIES AND THEIR USES
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
RU2357957C2 (ru) * 2003-03-03 2009-06-10 Эррэй Биофарма, Инк. Ингибиторы р38 и способы их применения
MXPA05009303A (es) * 2003-04-03 2005-10-05 Pfizer Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr.
EP1885338A1 (en) 2005-05-19 2008-02-13 Pfizer, Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor

Also Published As

Publication number Publication date
KR20070058690A (ko) 2007-06-08
BRPI0518203A2 (pt) 2009-03-10
CA2586174A1 (en) 2006-05-11
MX2007005291A (es) 2007-07-19
JP2008518900A (ja) 2008-06-05
TWI294421B (en) 2008-03-11
TW200621721A (en) 2006-07-01
AR051754A1 (es) 2007-02-07
EP1809621A1 (en) 2007-07-25
US20060094881A1 (en) 2006-05-04
US7232910B2 (en) 2007-06-19
RU2007116107A (ru) 2008-11-10
AU2005300310A1 (en) 2006-05-11
IL182693A0 (en) 2007-09-20
WO2006048744A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
NO20071619L (no) Fremgangsmate for fremstilling av indazol forbindelse
NO20071242L (no) Triazolpyridinylsulfanylderivater som P38-MAP-kinaseinhibitorer
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20082482L (no) Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
WO2007079164A3 (en) Protein kinase inhibitors
NO20072963L (no) 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
NO20090628L (no) Pyridizinon derivativater
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20066055L (no) Pyridinderivater
WO2008131000A3 (en) 7-substituted indole mcl-1 inhibitors
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
NO20081454L (no) Met-kinaseinhibitorer
WO2008061108A3 (en) Phthalazine derivatives
WO2008005877A3 (en) Inhibitors of c-kit and uses thereof
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application